Feasibility of electronic patient-reported outcomes implementation to enhance pancreatic cancer care delivery in a multidisciplinary health system.

504 Background: Electronic patient-reported outcomes (ePROs) are a component of high-quality pancreatic cancer care, but obstacles exist to implementation at scale to inform care across a complex health system. As part of the Canopy Cancer Collective initiative, the UCLA Agi Hirshberg Center for Pancreatic Diseases developed and implemented a model of ePRO-informed pancreatic cancer care, leveraging an oncology-specific care platform, Carevive. This study examines the feasibility of implementing ePROs in pancreatic cancer care, with attention to identifying key barriers and facilitators. Methods: Implementation was conducted from November 2024 to June 2025 incorporating the team’s Adaptive Interdisciplinary Model. Patients submitted baseline ePROs and could voluntarily enroll in the remote symptom monitoring (RSM) program. The baseline survey captured demographics as well as PROs focused on quality-of-life (QoL), symptoms, and overall health. The pre-implementation process involved identification of key stakeholders and formal SWOT analysis. In response to engagement challenges, a patient navigator with a defined clinic workflow was established to support patient enrollment and engagement. Continuous improvement efforts were followed to optimize implementation. Results: A total of 94 patients with pancreatic ductal adenocarcinoma with established and ongoing care at the center were identified. Of these, 59 patients (62.8%) submitted a baseline ePROs survey and 43 of them (72.9%) consented to enroll in the RSM program for ongoing monitoring. Of the 75 patients identified since January 2025, 51(68%) submitted a baseline survey; an increase from 42% prior to January 2025, exceeding the center’s 50% target completion rate. Optimization of the patient navigator’s clinic workflow is likely a contributing factor. Of all patients who submitted a baseline survey, the median age was 69, 57% were considered Intermediate Fit or Frail, and 74% indicated interest in trial participation. Fatigue, decreased appetite, anxiety, and insomnia were the most prevalent symptoms reported at baseline. Most patients indicated their QoL to be “6” and overall health to be a “5” on the EORTC-QLQ C30 (range: 1 (“Very poor”) to 7 (“Excellent”)). Conclusions: Routine collection of ePROs in a pancreatic cancer population is feasible and facilitated by the addition of a patient navigation workflow. The implementation enabled identification of symptom burden and QoL concerns. Facilitating factors included the following: engaged core team members, stakeholder support, a clearly defined conceptual model, use of an oncology-specific ePRO platform, utilization of a patient navigator role, and ongoing quality improvement efforts to optimize processes in real time. Next steps include measuring impact on patient experience and clinical outcomes of interest.